If you have a question relating to an adverse event or product complaint for an AstraZeneca product, please contact us on +64 9 306 5673 or by email at Regulatory.NZ@astrazeneca.com
Symbicort® Turbuhaler® 400/12
Symbicort Turbuhaler 400/12 contains budesonide 400µg (preventer) and eformoterol 12µg (symptom controller) per dose. Symbicort 400/12 is indicated for the regular treatment of asthma and moderate to severe COPD. Specific criteria apply for the use and funding of Symbicort. Not all patients are eligible for treatment with Symbicort. Ask your doctor if Symbicort is right for you. Use strictly as directed. Symbicort should not be initiated as emergency treatment for severe exacerbations or for patients with acutely worsening asthma symptoms. Do not use if you are allergic to budesonide or eformoterol. Tell your doctor if you have thyroid problems, heart problems, diabetes, problems with potassium levels, pregnancy, breast-feeding. Common side effects include mild irritation in the throat, coughing, hoarseness, thrush (fungal infection in mouth and throat), headache, trembling, fast or irregular heartbeat. Rarely, allergic reactions. Prescription Medicine. If symptoms continue or you experience side effects, see your healthcare professional. Your doctor’s fee and a prescription fee will apply.
For full Consumer Medicine Information for Symbicort Turbuhaler see www.medsafe.govt.nz. Symbicort and Turbuhaler are trademarks of AstraZeneca Group. AstraZeneca Limited, P299 Private Bag 92175, Auckland 1142, Telephone (09) 306 5650 Facsimile (09) 306 5651. TAPS NA 5723 APRIL 2012 essence AZ5730.
1. Symbicort Turbuhaler Data Sheet 31 October 2011.
2. Szafranski et al. European Respiratory
Journal 2003; 21:74-81.